Evidence map›Paper›PMID 36344041›Full record

ArticleJournal of pharmacological sciences2022

Effects of a novel hepatitis B anti-viral drug E-CFCP in renal organic acid transporters.

Misaki Ishibane, Hirofumi Hashimoto, Meika Kaneko, Shota Saito, Sangjon Pae, Shinpei Saito, Yoshie Reien, Yuri Hirayama, Nobuyo Higashi-Kuwata, Hiroaki Mitsuya and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of pharmacological sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 81% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Misaki IshibaneDepartment of Pharmacology, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo, Chiba 260-8670, Japan.
Hirofumi HashimotoDepartment of Pharmacology, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo, Chiba 260-8670, Japan.
Meika KanekoDepartment of Pharmacology, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo, Chiba 260-8670, Japan.
Shota SaitoDepartment of Pharmacology, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo, Chiba 260-8670, Japan.
Sangjon PaeDepartment of Pharmacology, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo, Chiba 260-8670, Japan.
Shinpei SaitoDepartment of Pharmacology, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo, Chiba 260-8670, Japan.
Yoshie ReienDepartment of Pharmacology, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo, Chiba 260-8670, Japan.
Yuri HirayamaDepartment of Pharmacology, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo, Chiba 260-8670, Japan.
Nobuyo Higashi-KuwataDepartment of Refractory Viral Infections, National Center for Global Health & Medicine Research Institute, Tokyo, Japan.
Hiroaki MitsuyaDepartment of Refractory Viral Infections, National Center for Global Health & Medicine Research Institute, Tokyo, Japan; Experimental Retrovirology Section, HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Naohiko AnzaiDepartment of Pharmacology, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo, Chiba 260-8670, Japan. Electronic address: anzai@chiba-u.jp.
Chiba University · JPNational Cancer Institute · USNational Center for Global Health and Medicine · JP

Funding

Development of Novel Agents Active against Hepatitis B VirusZIABC011486 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI MITSUYA, HIROAKI · 2013 to 2025
$3.0M
Intramural NIH HHS ZIA BC011486
6 · The paper itself

Abstract

Currently, the emergence of drug resistance is an important issue in the treatment of hepatitis B virus (HBV). Recently, our collaborating group developed a novel long-acting anti-HBV drug, E-CFCP. However, until this study, the effects of E-CFCP in the kidney have remained unclarified. Using cell viability and uptake assays, we examined the effects of E-CFCP on the function of renal organic anion transporters (OATs). No cytotoxicity was shown related to the E-CFCP in the renal OATs in either assay. Thus, this study suggested that E-CFCP may be a novel, excellent candidate drug for the treatment of drug-resistant HBV.

Indexed as

Hepatitis BOrganic Anion TransportersAntiviral AgentsDrug Resistance, ViralHepatitis B virusHumansKidneyMembrane Transport ProteinsAntiviral AgentsMembrane Transport ProteinsOrganic Anion TransportersKidney damageNucleoside reverse transcriptase inhibitorsRenal tubular cells

Identifiers

PMID36344041
PMCPMC10722831
OpenAlexW4297837820

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.